Robert M Rifkin1, Rafat Abonour2, Howard Terebelo3, Jatin J Shah4, Cristina Gasparetto5, James Hardin6, Shankar Srinivasan7, Rosanna Ricafort7, Yasir Nagarwala7, Brian G M Durie8. 1. US Oncology Research, The Woodlands, TX and Rocky Mountain Cancer Centers, Denver, CO. Electronic address: robert.rifkin@usoncology.com. 2. Indiana University Simon Cancer Center, Indianapolis, IN. 3. Newland Medical Associates, Novi, MI. 4. M.D. Anderson Cancer Center, Houston, TX. 5. Duke University Medical Center, Durham, NC. 6. University of South Carolina, Columbia, SC. 7. Celgene Corporation, Summit, NJ. 8. Cedars-Sinai Comprehensive Cancer Center, Los Angeles, CA.
Abstract
BACKGROUND: Connect MM is the first and largest observational, noninterventional, prospective registry of patients newly diagnosed with multiple myeloma (NDMM) in the United States. It collects longitudinal data on patients within clinical practice including patients in clinical trials. PATIENTS AND METHODS: Of the 1513 patients enrolled, 1493 were protocol-eligible. RESULTS: Median age was 67 years, 81.9% (1223/1493) were Caucasian, and 57.2% (854/1493) were male. Of these patients, 26.5% (232/877) were International Staging System stage I, 34.9% (306/877) stage II, and 38.7% (339/877) stage III. Eastern Cooperative Oncology Group performance status of 0/1/2 were reported in 96.6% (1017/1053). Clonal plasma cells > 10% were found in 91.6% (1282/1399) of patients and M-component in 98.8% (1343/1359). Hypercalcemia was present in 7.3% (108/1481) of patients, serum creatinine > 2 mg/dL in 18.3% (271/1484), anemia in 45.1% (673/1493), and bone involvement in 76.7% (1143/1490). Of the 15 National Comprehensive Cancer Network (NCCN) recommended diagnostic tests, a median of 12 were performed. Lactate dehydrogenase assessment, serum free light chain ratio, and immunofixation were reported in 38.4% (574/1493), 62.1% (927/1493), and 66% (985/1493) of patients, respectively. Quantitative immunoglobulin, β-2 microglobulin, and protein electrophoresis (serum or urine) were reported in 72.3% (1080/1493), 74.1% (1107/1493), and 78.0% (1164/1493) of patients, respectively. Bone marrow biopsy was reported in 92.2% (1376/1493), but conventional cytogenetic and fluorescence in situ hybridization analysis were reported in only 63.2% (944/1493) and 59.8% (893/1493) of patients, respectively. A high-risk cytogenetic profile (according to International Myeloma Working Group [IMWG] criteria) was found in 16.9% (253/1493). CONCLUSION: This analysis provides insight into the demographic and disease characteristics of NDMM patients in a range of clinical practices. Creating solid records of baseline patient disease characteristics using suggested NCCN diagnostic work-up and IMWG criteria provides a foundation for monitoring disease progression and response to treatment.
BACKGROUND: Connect MM is the first and largest observational, noninterventional, prospective registry of patients newly diagnosed with multiple myeloma (NDMM) in the United States. It collects longitudinal data on patients within clinical practice including patients in clinical trials. PATIENTS AND METHODS: Of the 1513 patients enrolled, 1493 were protocol-eligible. RESULTS: Median age was 67 years, 81.9% (1223/1493) were Caucasian, and 57.2% (854/1493) were male. Of these patients, 26.5% (232/877) were International Staging System stage I, 34.9% (306/877) stage II, and 38.7% (339/877) stage III. Eastern Cooperative Oncology Group performance status of 0/1/2 were reported in 96.6% (1017/1053). Clonal plasma cells > 10% were found in 91.6% (1282/1399) of patients and M-component in 98.8% (1343/1359). Hypercalcemia was present in 7.3% (108/1481) of patients, serum creatinine > 2 mg/dL in 18.3% (271/1484), anemia in 45.1% (673/1493), and bone involvement in 76.7% (1143/1490). Of the 15 National Comprehensive Cancer Network (NCCN) recommended diagnostic tests, a median of 12 were performed. Lactate dehydrogenase assessment, serum free light chain ratio, and immunofixation were reported in 38.4% (574/1493), 62.1% (927/1493), and 66% (985/1493) of patients, respectively. Quantitative immunoglobulin, β-2 microglobulin, and protein electrophoresis (serum or urine) were reported in 72.3% (1080/1493), 74.1% (1107/1493), and 78.0% (1164/1493) of patients, respectively. Bone marrow biopsy was reported in 92.2% (1376/1493), but conventional cytogenetic and fluorescence in situ hybridization analysis were reported in only 63.2% (944/1493) and 59.8% (893/1493) of patients, respectively. A high-risk cytogenetic profile (according to International Myeloma Working Group [IMWG] criteria) was found in 16.9% (253/1493). CONCLUSION: This analysis provides insight into the demographic and disease characteristics of NDMM patients in a range of clinical practices. Creating solid records of baseline patient disease characteristics using suggested NCCN diagnostic work-up and IMWG criteria provides a foundation for monitoring disease progression and response to treatment.
Authors: Sundar Jagannath; Rafat Abonour; Brian G M Durie; Mohit Narang; Howard R Terebelo; Cristina J Gasparetto; Kathleen Toomey; James W Hardin; Lynne Wagner; Amit Agarwal; Shankar Srinivasan; Amani Kitali; E Dawn Flick; Michael Sturniolo; Robert M Rifkin Journal: Blood Adv Date: 2018-07-10
Authors: Monika Engelhardt; Gabriele Ihorst; Ola Landgren; Milena Pantic; Heike Reinhardt; Johannes Waldschmidt; Annette M May; Martin Schumacher; Martina Kleber; Ralph Wäsch Journal: Haematologica Date: 2015-07-09 Impact factor: 9.941
Authors: Howard Terebelo; Shankar Srinivasan; Mohit Narang; Rafat Abonour; Cristina Gasparetto; Kathleen Toomey; James W Hardin; Gail Larkins; Amani Kitali; Robert M Rifkin; Jatin J Shah Journal: Am J Hematol Date: 2017-07-19 Impact factor: 10.047
Authors: Rafat Abonour; Lynne Wagner; Brian G M Durie; Sundar Jagannath; Mohit Narang; Howard R Terebelo; Cristina J Gasparetto; Kathleen Toomey; James W Hardin; Amani Kitali; Craig J Gibson; Shankar Srinivasan; Arlene S Swern; Robert M Rifkin Journal: Ann Hematol Date: 2018-07-29 Impact factor: 3.673
Authors: Paul G Richardson; Jesus F San Miguel; Philippe Moreau; Roman Hajek; Meletios A Dimopoulos; Jacob P Laubach; Antonio Palumbo; Katarina Luptakova; Dorothy Romanus; Tomas Skacel; Shaji K Kumar; Kenneth C Anderson Journal: Blood Cancer J Date: 2018-11-09 Impact factor: 11.037
Authors: Sikander Ailawadhi; Sundar Jagannath; Mohit Narang; Robert M Rifkin; Howard R Terebelo; Kathleen Toomey; Brian G M Durie; James W Hardin; Cristina J Gasparetto; Lynne Wagner; James L Omel; Vivek Kumar; Lihua Yue; Amani Kitali; Amit Agarwal; Rafat Abonour Journal: Cancer Med Date: 2019-11-07 Impact factor: 4.452
Authors: Sikander Ailawadhi; Sundar Jagannath; Hans C Lee; Mohit Narang; Robert M Rifkin; Howard R Terebelo; Brian G M Durie; Kathleen Toomey; James W Hardin; Cristina J Gasparetto; Lynne Wagner; James L Omel; Mia He; Lihua Yue; Elizabeth Dawn Flick; Amit Agarwal; Rafat Abonour Journal: Cancer Date: 2020-07-24 Impact factor: 6.860
Authors: Howard R Terebelo; Rafat Abonour; Cristina J Gasparetto; Kathleen Toomey; Brian G M Durie; James W Hardin; Sundar Jagannath; Lynne Wagner; Mohit Narang; E Dawn Flick; Shankar Srinivasan; Lihua Yue; Amani Kitali; Amit Agarwal; Robert M Rifkin Journal: Br J Haematol Date: 2019-08-05 Impact factor: 6.998
Authors: Rafat Abonour; Robert M Rifkin; Cristina Gasparetto; Kathleen Toomey; Brian G M Durie; James W Hardin; Howard R Terebelo; Sundar Jagannath; Mohit Narang; Sikander Ailawadhi; James L Omel; Hans C Lee; Shankar Srinivasan; Amani Kitali; Amit Agarwal; Lynne Wagner Journal: Br J Haematol Date: 2020-10-29 Impact factor: 6.998